logo-loader
RNS
Amryt Pharma PLC

Suspension - Amryt Pharma plc

/**/ .l{size:595.3pt 841.9pt;margin:72.0pt 90.0pt 72.0pt 90.0pt;}div.l{}p.t{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Arial","sans-serif";font-weight: bold}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Arial","sans-serif";}span.q{font-size:11.0pt}p.u{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Arial","sans-serif";font-weight: bold; text-autospace: none}span.p{font-size:11.0pt; color:black}p.v{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Arial","sans-serif";text-autospace:none}span.m{font-size:10.5pt;color:black} /**/
RNS Number : 6683Z
AIM
21 May 2019
 

 

 

 

NOTICE

 

21/05/2019 7:30am

 

TEMPORARY SUSPENSION OF TRADING ON AIM

 

AMRYT PHARMA PLC

 

At the request of the Company trading on AIM for the under-mentioned securities has been temporarily suspended from 21/05/2019 7:30am, pending publication of an admission document.

 

ORDINARY SHARES OF 1P EACH, FULLY PAID (BDD1LS5) (GB00BDD1LS57)

 

If you have any queries relating to the above, please contact the company's nominated adviser on +44 (0) 20 7408 4090.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
EXCCKDDKABKKOPB

Quick facts: Amryt Pharma PLC

Price: £1.29

Market: AIM
Market Cap: £64.99 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Orphan drug status for new compound 'great news' says Amryt Pharma PLC's COO

Amryt Pharma PLC (LON:AMYT) has been granted orphan drug status in the US for  a compound called AP102 to treat patients with the excess growth condition acromegaly. Chief operating officer Rory Nealon tells Proactive: ''Our focus is to acquire, develop and commercialise products in the...

on 11/07/2016

RNS

Circular to Shareholders

3 days, 23 hours ago

Update on Acquisition of Aegerion

5 days, 15 hours ago

Schedule One

1 week, 5 days ago

Schedule One - Amryt Pharma plc

1 week, 5 days ago

Holdings in Company

2 weeks ago

Holding(s) in Company

2 weeks, 4 days ago